131530
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 25
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.779122846
- umap2_2d
- 1.175433766
- umap1_3d
- -0.12442843
- umap2_3d
- 2.75215034
- umap3_3d
- -1.997114231
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.400
- MYC_TARGETS_V2+0.370
- HYPOXIA+0.340
- IL6_JAK_STAT3_SIGNALING+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- UV_RESPONSE_UP+0.280
- MYOGENESIS+0.260
- MITOTIC_SPINDLE+0.240
- APICAL_JUNCTION+0.230
- ESTROGEN_RESPONSE_EARLY+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.360
- OXIDATIVE_PHOSPHORYLATION-0.270
- FATTY_ACID_METABOLISM-0.260
- MYC_TARGETS_V1-0.240
- SPERMATOGENESIS-0.240
- PROTEIN_SECRETION-0.220
- BILE_ACID_METABOLISM-0.170
- E2F_TARGETS-0.140
- NOTCH_SIGNALING-0.140
- INTERFERON_GAMMA_RESPONSE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02289 | — | cohortSQ1 | 0.755 |
| 2 | C3L-02660 | — | cohortSQ1 | 0.732 |
| 3 | MNG184 | — | — | 0.718 |
| 4 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.714 |
| 5 | R104 | — | — | 0.693 |
| 6 | BS_196BBNEJ | EPN | Posterior Fossa EPN | 0.684 |
| 7 | 299613f5-2f9a-4687-ab0c-323bf38f3699 | — | — | 0.681 |
| 8 | TCGA-58-8386-01A-11R-2296-07 | — | cohortSQ1 | 0.671 |
| 9 | TCGA-56-5898-01A-11R-1635-07 | — | cohortSQ1 | 0.667 |
| 10 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.665 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |